$IVF Cashflow Statement | Understand Stock

$IVF

$0.54 -$0.02 (3.6%) Close

$IVF Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock compensation issued for services
Non-cash stock compensation issued to directors and/or employees
Fair value of stock options issued to employees
Non-cash compensation for services
Amortization of discount on notes payable
Amortization of leasehold right of use asset
Loss on impairment of intangible assets
Loss from equity method investment
Impairment loss
Reserve on other assets
(Gain) Loss from equity method investment
Impairment from equity method joint venture
Loss from debt extinguishment
Loss on disposal of fixed assets
Gain on lease termination
Loss on disposition
Fair value of warrants
Gain on changes in fair value
Gain on settlement
Depreciation and amortization
Changes in assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Equity investments
Accounts payable and accrued expenses
Accrued compensation
Deferred revenue
Other current liabilities
Leasehold liability
Accrued interest
Income taxes payable
Deferred tax liabilities

Net cash used in operating activities
Cash used in investing activities:
Payments to acquire property, plant, and equipment
Payments to acquire intangible assets
Proceeds from sale of fixed assets
Cash acquired in acquisition
Investment in joint ventures
Divesture of NTI
Payment for acquisitions
Net cash used in investing activities

Cash from financing activities:
Proceeds from notes payable – related parties
Proceeds from notes payable
Proceeds from the sale of common stock, net of offering costs
Proceeds from the sale of preferred stock
Proceeds from unit purchase option exercise
Proceeds from option exercise
Preferred stock redemption
Principal payments on notes payable
Net cash provided by financing activities

Increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Interest
Taxes

Noncash activities:
Common stock issued upon note payable and accrued interest conversion
Common stock issued upon conversion notes payable and accrued interest
Fair value of preferred stock issued for acquisition
Common stock and preferred stock issued upon conversion notes payable and accrued interest
Dividends on preferred stock
Deemed dividend
Fair value of warrants issued with debt
Fair value of common stock issued with debt
Fair value of shares issued for settlement of liability
Cashless exercise of warrants
Cashless exercise of unit purchase options
Fixed assets transferred to investment in joint venture
Initial ROU asset and lease liability
Fair value of Series B preferred shares issued in exchange for shares of NAYA common stock
C-2 to common stock exchange
Preferred stock redemption adjustment
Preferred stock exchange
Common stock issued for accounts payable

Comments